|Day Low/High||69.91 / 70.83|
|52 Wk Low/High||55.06 / 75.04|
Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.
Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.
- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment
- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*
What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.
Stock futures are lower.
U.S. stock futures fall as earnings from Amazon.com disappoint.
Wall Street's first glimpse at the second quarter.
- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy
Remarkable data was released from Vertex's triple regiment combination trials.
Tech companies aren't the only ones seeing their shares rise this year.
Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.
Players include Apple, Google, Microsoft and Samsung.
Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.
Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.
- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*
Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
AbbVie's June rally has now driven shares past the 2016 high.
- IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment